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Background: Many journals prohibit the use of declarative titles that state study findings, yet a few journals
encourage or even require them. We compared the effects of a declarative versus a descriptive title on readers’
perceptions about the strength of evidence in a research abstract describing a randomized trial.
Methods: Study participants (medical or dental students or doctors attending lectures) read two abstracts
describing studies of a fictitious treatment (Anticox) for a fictitious condition (Green’s syndrome). The first abstract
(A1) described an uncontrolled, 10-patient, case series, and the second (A2) described a randomized, placebo-
controlled trial involving 48 patients. All participants rated identical A1 abstracts (with a descriptive title) to provide
baseline ratings and thus reduce the effects of inter-individual variability. Participants were randomized so that half
rated a version of A2 with a descriptive title and half with a declarative title. For each abstract, participants
indicated their agreement with the statement “Anticox is an effective treatment for pain in Green’s syndrome”
using 100 mm visual analogue scales (VAS) ranging from “disagree completely” to “agree completely.” VAS scores
were measured by an investigator who was unaware of group allocation.
Results: One hundred forty-four participants from four centres completed the study. There was no significant
difference between the declarative and the descriptive title groups’ confidence in the study conclusions as
expressed on VAS scales—in fact, the mean difference between A1 and A2 was smaller for the declarative title
group than that for the descriptive title group (32.6 mm, SD 27.4 vs. 39.8 mm, SD 22.6, respectively, p = 0.09).
Conclusions: We found no evidence that the use of a declarative title affected readers’ perceptions about study
conclusions. This suggests that editors’ fears that declarative titles might unduly influence readers’ judgements
about study conclusions may be unfounded, at least in relation to reports of randomized trials. However, our study
design had several limitations, and our findings may not be generalizable to other situations.
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Many textbooks and journal instructions about how to
write research articles state that the title is “the most im-
portant part of a scientific article,” and Lang has sug-
gested that “It is the part most often read and often the
only part read [1].” Despite their importance, there is no
consensus on the most appropriate style for titles. Art-
icle titles may be classified as either descriptive or de-
clarative. Descriptive (or indicative) titles describe the* Correspondence: liz@sideview.demon.co.uk
1Sideview, Station Road, Princes Risborough HP27 9DE, UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zestudy topic and design. Declarative (or informative) titles
state the study findings [2]. Confusingly, while many
journals prohibit the use of declarative titles, a few jour-
nals encourage or even require them [3–5]. At least in
some disciplines, the use of declarative titles has in-
creased since the mid-1980s [6].
In the absence of any published evidence about their
merits or dangers, opinions about title styles appear
strongly held. Aronson claims “At best, declarative titles
mislead; at worst they may enshrine a falsehood as a per-
manent truth [5].” In contrast, the instructions to au-
thors for Microbiology state “A title that emphasizes thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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than one that just describes the nature of the study [4].”
Given these contradictory positions, and an apparent
absence of evidence for such dogmas, we attempted to
compare the effects of declarative and descriptive titles
on readers’ perceptions about the findings of a random-
ized trial.Methods
This was a parallel group, randomized trial. Participants
were doctors or senior medical or dental students at-
tending lectures on evidence-based medicine or critical
evaluation at four UK institutions (Peninsula College of
Medicine and Dentistry, Plymouth and Exeter; Univer-
sity Hospital, Lewisham, London; Queen Mary, Univer-
sity of London) and the University of Split School of
Medicine, Croatia. All participants were either practising
medicine in the UK or taking an English language med-
ical course and were therefore fluent in English. The
study took place between January and June 2013. Since
the study did not involve the collection of any personal
or medical information, Research Ethics Committee ap-
proval was waived at all centres.
The study was introduced to participants as a study
“about research reporting” just before or after a lecture
(the timing of the study and the nature of the lecture
were controlled by the local organizers). Anybody at-
tending the lecture was eligible to take part. There was
no formal enrollment, and no personal details were col-
lected. The lecturers were instructed to emphasize that
participation was voluntary and those who preferred not
to take part could opt out by not taking, or not return-
ing, a study form. The potential participants were pre-
sented with two abstracts describing studies of the
efficacy of a fictitious treatment (Anticox) for a fictitious
condition (Green’s syndrome). The first abstract (A1) de-
scribed an uncontrolled, 10-patient, case series, and the
second (A2) described a randomized, placebo-controlled
trial involving 48 patients (the titles and abstracts are
available in Appendix 1). The study form comprised a
single sheet of A4 paper with instructions for comple-
tion at the top, followed by abstract A1 and a VAS scale
on one side, and abstract A2 and another VAS scale on
the other side. All participants rated identical A1 ab-
stracts (which had a descriptive title). The A1 abstract
was included to provide a baseline in an attempt to con-
trol for the fact that people’s levels of scepticism were
expected to vary, and we expected some people to be
“tougher” raters than others. Participants were random-
ized in a 1:1 ratio, so that half received a version of A2
with a descriptive title (Anticox versus placebo in
Green’s syndrome: results of a randomized trial) and half
received a version with a declarative title (Anticoxreduces pain in Green’s syndrome: results of a random-
ized placebo-controlled trial).
Randomization was achieved by supplying study forms
to each centre in a random sequence (achieved by the
investigator (EW) shuffling the forms before posting
them) and asking lecturers to distribute the forms in a
way that was likely to retain the random distribution
among participants (e.g., letting participants pick up
forms from a mixed pile as they entered the lecture or
handing out forms in a random order once participants
were seated). In this way, neither the lecturer nor the
participants could predict the group allocation. (The in-
vestigator, EW, was also unaware of the allocation as she
was not present when the forms were distributed.) The
two types of form were identical on one side (showing
abstract A1) and could only be distinguished by being
turned over and comparing the titles for abstract A2.
Participants read and rated the abstracts without dis-
cussing them with other participants. Participants were
therefore unaware of the design or purpose of the study.
For each abstract, participants indicated their agree-
ment with the statement “Anticox is an effective treat-
ment for pain in Green’s syndrome” using 100 mm
visual analogue scales (VAS) ranging from “disagree
completely” to “agree completely.” Our hypothesis was
that the difference in perceptions of efficacy between A1
and A2 would be greater when A2 had a declarative title.
VAS scores were measured by an investigator (EW) who
was unaware of group allocation (this was achieved by
masking the top of the form so that the title could not
be seen while the VAS score was measured). The pre-
specified primary outcome was the difference in VAS
scores between A1 and A2 in the declarative and de-
scriptive title groups. No secondary outcomes were
measured.Statistical methods
As we could find no similar published studies, we could
not predict the size of the difference nor the amount of
variability within the groups that we were likely to find.
It was therefore not possible to do a power calculation.
We used a two-sided t test to analyse the difference in
VAS scores between A1 and A2 in the declarative and
descriptive title groups. We used analysis of covariance
to take account of any differences between the groups in
scores for abstract A1 [7].
An interim analysis was performed in February 2013
using data from 79 participants from three centres. This
analysis was used to submit an abstract to the World
Congress on Peer Review but the results were not pub-
lished or communicated to the centres. The full analysis
was presented in the final abstract and as a poster at the
congress (September 2013).
Fig. 1 Distribution of VAS scores
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Completed forms were returned by 144 participants
(123 from UK centres, 21 from Croatia). We did not rec-
ord the number of potential participants who declined
to take part, but those administering the study reported
that very few people opted out. Demographic data were
not collected.
There was no significant difference between the de-
clarative and descriptive title groups’ views about study
conclusions as expressed on VAS scales. In fact, con-
trary to our expectations, the mean difference between
A1 and A2 was smaller when A2 had a declarative title
(32.6 vs. 39.8 mm, p = 0.09, see Table 1). There was a
notable difference of 6.2 mm between the groups in
their mean A1 scores, however. Using the analysis of
covariance to take account of that, the difference be-
tween the declarative and descriptive groups was
2.4 mm and remained non-significant, p = 0.42, see
Table 1 and Fig. 1.
Discussion
We found that using a declarative title had no significant
effect on readers’ perceptions of the conclusions of a
randomized trial reported in an abstract. In fact, readers’
confidence in the findings was slightly lower when they
received an abstract with a declarative title (but the dif-
ference was not statistically significant).
Our study had several limitations. Without an accurate
estimate of the effect size or variance, it was not possible
to calculate statistical power and it is therefore possible
that the study was under-powered or insensitive to small
effects, although we considered 144 participants to be a
reasonable sample for such a study. We used abstracts
rather than full journal articles so that the study could
be completed quickly and be fitted in at the beginning
or end of a lecture. It is possible that readers’ percep-
tions of abstracts and full papers, and therefore the ef-
fects of their title styles, are different, so our findings
may not be generalizable to full articles. It is also
possible that responses were affected by the fact that par-
ticipants were attending a lecture on evidence-based
medicine or critical evaluation rather than reading a publi-
cation in other circumstances. We asked participants toTable 1 Mean VAS scores for reader confidence in study conclusion
represent greater agreement with a statement on the study conclus
Descriptive title group
(n = 70) [mean (SD)]
A1 VAS scoreb 34.4 (21.5)
A2 VAS scoreb 74.2 (17.0)
Difference (A2–A1) 39.8 (22.6)
Adjusted differenceb
aTwo-sided p value from t test
bAnalysis of covariancerate the two abstracts in an attempt to reduce inter-
rater variability. However, having previously read the
abstract describing the case series (A1) may have af-
fected readers’ perceptions of the second abstract
(which described a randomized trial). For example, it is
possible that, having just read abstract A1, participants
read abstract A2 more quickly—perhaps even skipping
the title or paying less attention to it than if they had
read only one publication.
We did not collect any personal details from the par-
ticipants as we did not intend any sub-group analyses
and did not expect sex, age, training, specialty, or experi-
ence to be important influencing factors. Our sample
comprised both practising doctors and senior medical
and dental students to reflect the range of people likely
to read reports of clinical trials.
Despite these limitations, we believe our findings are
interesting. In particular, we found no evidence to sup-
port many editors’ contention that declarative titles
over-influence readers and reinforce study conclusions
inappropriately.s for abstracts with descriptive or declarative titles (higher scores
ions)
Declarative title group
(n = 74) [mean (SD)]
Difference between
groups (95 % CI)
40.6 (23.9)
73.2 (20.3)
32.6 (27.4) −7.2 (–15.5 to 1.1) p = 0.09a
−2.4 (–8.5 to 3.6) p = 0.42
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gest that they may make articles more attractive (an as-
pect we did not attempt to measure in this study) or
more effective in communicating their message. Richard
Smith (when editor of The BMJ) wrote “journalists, who
know a thing or two about getting people to read what
they write, believe strongly in the use of declarative titles
and the inclusion of active verbs. “Freddie Starr ate my
hamster” is one of the great titles of our time. “Freddie
Starr and my hamster: a personal account” would have
long been forgotten [8].” The ACP Journal Club has sug-
gested “By disclosing each article’s conclusion in its
title, we hope to help busy clinical readers become
even more efficient in their efforts to keep up with
the literature [9].”
However, one motivation for doing the study, apart
from contradictory journal instructions, was to test the
observation from Daniel Kahneman that “A reliable way
to make people believe in falsehoods is frequent repeti-
tion, because familiarity is not easily distinguished from
truth” [10]. One objection to the use of declarative titles
might be that they serve to repeat the study’s conclusion
and, in fact, present it before readers have had a chance
to assess the study. If the conclusion is unjustified, over-
simplified, or misleading, this repetition could be harm-
ful. On the other hand, if declarative titles help readers
understand the article, such repetition could be benefi-
cial. However, our hypothesis that using a declarative
title would increase readers’ confidence in the study
findings was not borne out.
Given the prohibition on declarative titles in numer-
ous journals, many editors appear to side with Jeff
Aaronson who denounced them in 2010 [5] and Jonah
Rosner who criticised their use in the biology literature
in 1990, suggesting that they were “impudent and im-
prudent” [11].
Despite the strongly expressed views, we found only
two published studies relating to title style but none
measuring effects on reader perceptions. Neville Good-
man assessed study reports listed in Medline between
1970 and 1997 that included selected active verbs (such
as “prevents” or “reduces”) in their title [12]. Using this
method, he observed a clear increase in the use of de-
clarative titles over that period. He also concluded that
many of the declarative titles were “over-optimistic” (for
example, 8 of 24 reports using the word “prevent” re-
ported studies in which disease incidence was reduced
rather than completely prevented). He concluded that
“There may be arguments for reviews and editorials car-
rying informative titles, but [they] have little place in the
reporting of research.” This may explain why declarative
titles appear to be more commonly permitted (or en-
couraged) in journals about evidence-based medicine
(such as Evidence-Based Medicine and the Journal ofClinical Epidemiology) than in journals reporting pri-
mary, clinical research.
Jonah Rosner studied the frequency of what he termed
“assertive sentence titles” in biology publications from
1969 to 1989 [11]. He reported that they started being
used in 1970 and had increased in frequency since then,
being especially common in molecular biology. Like
Goodman, he was concerned that such titles often con-
veyed an over-simplified interpretation of the research
and he condemned their use.
More recently, Letchford and colleagues analysed
140,000 articles on the Scopus database and showed that
those with shorter titles tended to attract more citations
than those with longer titles [13]. They did not study the
effects of title style although, interestingly, they used a
declarative title for their own article.
While many journals have policies about declarative ti-
tles, less attention appears to be paid to use of the ques-
tion (or interrogatory) style (such as the one we used for
this article). We are aware (from our own experiences)
that a few journals discourage or ban its use while others
(such as Microbiology [3]) encourage it, but we have not
studied this systematically.
Conclusions
Our small, exploratory study neither supports nor chal-
lenges journal bans on declarative titles but may reassure
editors that such titles are, perhaps, not as harmful as
has sometimes been claimed. Larger studies, with a
broader range of participants, in different settings and
using different study designs are needed to understand
this issue better. Sadly, given the cost of medical re-
search and the importance of communicating its find-
ings effectively and without distortion, there has been
remarkably little research into the effects of reporting
formats and styles on reader comprehension and percep-
tion [14, 15]. We encourage editors, publishers, and fun-
ders to remedy this and provide the basis for evidence-
based research reporting.
Appendix 1
The abstracts used in the study
A1
Effects of anticox on pain in Green’s syndrome: a case
series
Background: Green’s syndrome is a rare form of food
allergy characterized by pain in joints and muscles that
is usually unresponsive to conventional analgesics.
Anticox is a novel anti-inflammatory agent that acts on
a pain pathway believed to be involved in Green’s syn-
drome. We tested the effect of anticox on pain in pa-
tients with Green’s syndrome.
Methods: Ten patients with suspected Green’s syn-
drome were given 50 mg anticox tablets, twice daily for
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ing worst pain experienced that day using a 100 mm vis-
ual analogue scale (VAS). The main outcome measure
was the difference in mean pain scores between Day 1
and Day 10.
Results: Eight of the 10 patients reported less pain on
Day 10 than Day 1. The mean difference in pain scores
was 18.3 mm (standard deviation 4.6).
Conclusions: Anticox may reduce the pain associated
with Green’s syndrome.
A2 (participants were randomized to receive either the
descriptive or the declarative title)




Anticox reduces pain in Green’s syndrome: results of a
randomized placebo-controlled trial
[declarative title]
Background: Green’s syndrome is a rare form of food
allergy characterized by pain in joints and muscles that
is usually unresponsive to conventional analgesics.
Anticox is a novel anti-inflammatory agent that acts on
a pain pathway believed to be involved in Green’s syn-
drome. We tested the effect of anticox on pain in pa-
tients with Green’s syndrome.
Methods: 48 adult patients with serologically con-
firmed Green’s syndrome were randomized and given ei-
ther 50 mg anticox or matching placebo tablets, twice
daily for 10 days. Participants completed a daily pain
diary recording worst pain experienced that day using a
100 mm visual analogue scale (VAS). The main outcome
measure was the difference in mean pain scores between
Day 1 and Day 10.
Results: 44 patients completed the study and provided
pain data. The mean difference in pain scores between
Day 1 and Day 10 was 28.4 mm in the anticox group
(n = 23) and 7.1 mm in the placebo group (n = 21).
This difference was statistically significant (p = 0.01). Two
patients in the anticox group reported abdominal pain.
Conclusions: Anticox reduces pain in Green’s syndrome.Acknowledgements
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